Bone marrow trephine biopsy involvement by lymphoma: review of histopathological features in 511 specimens and correlation with diagnostic biopsy, aspirate and peripheral blood findings

Sovani, Vishakha; Harvey, Caroline; Haynes, Andrew; McMillan, Andrew; Clark, David M.; O’Connor, Simon

doi:10.1136/jclinpath-2013-201520

Cited by 51 publications

(34 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…FL shows a predominantly paratrabecular pattern in 76-90% of cases (26,27), whereas in more aggressive lymphomas such as DLBCL, diffuse and nodular patterns are more frequent (26).…”

Section: Resultsmentioning

confidence: 99%

Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy

et al. 2017

View full text Add to dashboard Cite

Background: Non-Hodgkin's lymphoma (NHL) accounts for around 4% of new cancer cases annually. Bone marrow involvement is important for staging and management. FDG PET/CT is used increasingly to identify this, in addition to bone marrow biopsy (BMB), which is seen as 'gold' reference standard. Results: Twenty-four patients with DLBCL and 12 with FL were included. Five DLBCL patients had bone marrow involvement on PET/CT; all were confirmed on BMB. Three FL patients had marrow involvement on PET/CT but not on BMB; one FL patient had positive BMB but negative PET/CT. Using BMB as the reference standard, the sensitivity and specificity of FDG PET/CT for detecting bone marrow involvement in DLBCL were 100% and 100%, respectively, and in FL were 0% and 72.7%, respectively. Conclusion

show abstract

“…FL shows a predominantly paratrabecular pattern in 76-90% of cases (26,27), whereas in more aggressive lymphomas such as DLBCL, diffuse and nodular patterns are more frequent (26).…”

Section: Resultsmentioning

confidence: 99%

Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In this PDX model, the primary MCL tumor metastasized to the lymph nodes, spleen, bone marrow, and gastrointestinal tract of the host mice, mimicking MCL clinical features. Bone marrow involvement has been reported in diffuse large B-cell lymphoma (DLBCL) (15), follicular lymphoma (FL) (16), marginal zone lymphoma (MZL) (17), and Burkitt’s lymphoma (BL) (18), with a significantly poor prognosis for patients with this involvement (19,20). Thus, we developed various B-cell lymphoma PDX models and recapitulated the pathological and clinical characteristics, molecular profiles, disease progression, and response to therapeutic agents in these B-cell lymphoma PDXs.…”

Section: Introductionmentioning

confidence: 99%

B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy

Zhang

Nomie

Zhang

et al. 2017

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose Patients with B-cell lymphomas often relapse after frontline therapy, and novel therapies are urgently needed to provide long-term remission. We established B-cell lymphoma PDX (patient-derived xenograft) models to assess their ability to mimic tumor biology and to identify B-cell lymphoma patient treatment options. Experimental Design We established the PDX models from 16 patients with diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, or Burkitt’s lymphoma by inoculating the patient tumor cells into a human bone chip implanted into mice. We subjected the PDX models to histopathological and phenotypical examination, sequencing, and drug efficacy analysis. Primary and acquired resistance to ibrutinib, an oral covalent inhibitor of Bruton’s tyrosine kinase, were investigated to elucidate the mechanisms underlying ibrutinib resistance and to identify drug treatments to overcome resistance. Results The PDXs maintained the same biological, histopathological, and immunophenotypical features, retained similar genetic mutations and produced comparable drug responses with the original patient tumors. In the acquired ibrutinib-resistant PDXs, PLC-γ2, p65, and Src were down-regulated; however, a PI3K signaling pathway member was up-regulated. Inactivation of the PI3K pathway with the inhibitor idelalisib in combination with ibrutinib significantly inhibited the growth of the ibrutinib-resistant tumors. Furthermore, we used a PDX model derived from a clinically ibrutinib-relapsed patient to evaluate various therapeutic choices, ultimately eliminating the tumor cells in the patient’s peripheral blood. Conclusions Our results demonstrate that the B-cell lymphoma PDX model is an effective system to predict and personalize therapies and address therapeutic resistance in B-cell lymphoma patients.

show abstract

“…Also in another work by EL Bolkeney et al, 2009 where the incidence of B-cell phenotype NHL was the major type ( 98%) and the T-cell NHL phenotype was only (2%) [7,8].…”

Section: Discussionmentioning

confidence: 99%

“…[11] In other work by Sovani et al, reported the follicular lymphoma as the commonest lymphoma to invade the marrow 26.2% followed by Lymphoplasmacytic 19.2% and DLBL 12.5%. [7] Another study by Arber and George, reported that follicular lymphoma (37.5%) was the most common type to involve the marrow, followed by diffuse large B-cell lymphoma (16.0%). This difference can be attributed due to the high number of Follicular lymphoma included in Sovani and Arber studies and also unequal proportions of patients with early and advanced stage of non Hodgkin's lymphoma.…”

Section: -138-mentioning

confidence: 97%

Diagnostic and Prognostic Significance of Bone Marrow Biopsy in Non Hodgkins Lymphoma

Ahmad

Esh

Khorshed

et al. 2017

Zagazig University Medical Journal

View full text Add to dashboard Cite

Background: Trephine bone marrow biopsy is the standard method for the diagnosis of neoplasia. In the last few years its role has been defined further by the widespread introduction of immunohistochemistry (IHC), the method that increased the diagnostic power of the trephine bone marrow biopsy by detecting specific antigens in the tumor tissue using nonflourescent chromogens that can be seen by conventional microscopy. Objective: to evaluate the diagnostic and prognostic significance of bone marrow biopsy in non-Hodgkin's lymphomas. Correlation of bone marrow biopsy finding with other prognostic markers in non-Hodgkin's lymphomas is another aim. Methods:The study was performed on 50 patients of NHL diagnosed by LN histopathology. All patients were subjected to: clinical examination and laboratory investigations including complete blood picture, liver function tests, kidney function tests, Erythrocyte sedimentation rate, serum lactate dehydrogenase, B2 microglobulin, bone marrow aspiration, immunophenotyping of bone marrow aspiration of the disseminated cases, bone marrow trephine biopsy for: histological classification according to WHO, staging of NHL and Immunohistochemical staining for CD3 and CD20. Results: Twenty patients (40%) positive for infiltration on examination of marrow biopsy and 30 patients (60%) were negative. The results of fifty NHL cases showed only in six cases, both bone marrow biopsy and aspiration were positive (12%; 95% CI, 4.0: 22.0), and in 30 out of 50, the two parameters were negative (60%, 95%CI, 46: 54). Thus, the agreement level between BMB and BMA in the diagnosis of NHL was 27% and discrepancies between bone marrow biopsy and aspirate were found in the remainder. In 14 of 50 specimens, BMB alone was positive (28%; 95% CI, 16 : 42). Conclusion: Bone marrow biopsy morphology and immunohistochemical staining remain the cornerstone for proper staging in NHL patients to increase the diagnostic and prognostic accuracy, for appropriate treatment protocols.

show abstract

Bone marrow trephine biopsy involvement by lymphoma: review of histopathological features in 511 specimens and correlation with diagnostic biopsy, aspirate and peripheral blood findings

Cited by 51 publications

References 29 publications

Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy

Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy

B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy

Diagnostic and Prognostic Significance of Bone Marrow Biopsy in Non Hodgkins Lymphoma

Contact Info

Product

Resources

About